C. R. Bard(NYSE:BCR) said today that its Lutonix 035 drug-coated balloon PTA catheter won premarket approval from the FDA and is available in the U.S.
The company’s Lutonix 035 device is the first drug-coated balloon approved in end-stage renal disease patients with stenotic lesions in dialysis arteriovenous fistulae. Bard’s DCB is also approved to treat superficial femoral artery and popliteal artery disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Bard lands new indication for its drug-coated balloon appeared first on MassDevice.
from MassDevice http://ift.tt/2xGnIGI
Cap comentari:
Publica un comentari a l'entrada